Name: Fondaparinux Sodium (Org 31540)
Brand: Selleck Chemicals
SKU: S3736
Rating: 5 (1 reviews)

Fondaparinux Sodium (Org 31540, Natural heparin pentasaccharide, Fondaparin, SR-90107A) is a synthetic glucopyranoside with antithrombotic activity. It selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin; a synthetic inhibitor of Factor Xa.

Fondaparinux Sodium (Org 31540) Chemical Structure

CAS: 114870-03-0

Purity & Quality Control

Batch: Purity: >97%

97

Fondaparinux Sodium (Org 31540) Related Products

Related Products	Apixaban Rivaroxaban Edoxaban tosylate Monohydrate Edoxaban Betrixaban Betrixaban maleate	Click to Expand
Related Compound Libraries	Metabolism Compound Library Anti-cancer Metabolism Compound Library Glutamine Metabolism Compound Library Carbohydrate Metabolism Compound Library Lipid Metabolism Compound Library	Click to Expand

Signaling Pathway

Factor Xa Signaling Pathway

Choose Selective Factor Xa Inhibitors

Biological Activity

Description

Fondaparinux Sodium (Org 31540, Natural heparin pentasaccharide, Fondaparin, SR-90107A) is a synthetic glucopyranoside with antithrombotic activity. It selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin; a synthetic inhibitor of Factor Xa.

Targets

Factor Xa ^[1]

In vitro
In vitro	Fondaparinux is a synthetic pentasaccharide that selectively inhibits factor Xa (FXa) in the coagulation cascade. Fondaparinux has been shown to inhibit the TF-FVIIa complex and FIXa in vitro^[1].
Cell Research	Cell lines	U937 cells
	Concentrations	0-100 μg/ml
	Incubation Time	30 min
	Method	Fondaparinux was diluted in PBS to a total volume of 50 μL and added to the wells. Labeled U937 cells (50 μL) were then added and incubated at room temperature for 30 min. Finally, the wells were washed three times with PBS and cells were lyzed using 2% Triton X-100 in 0.1 mol/L Tris-HCl pH 9.5.

In Vivo
In vivo	Fondaparinux reduces kidney I/R injury primarily by inhibiting the recruitment of neutrophil. It dramatically reduced fibrin deposition in the kidney^[1]. Fondaparinux can promote the stability of atherosclerotic lesions in apolipoprotein E-deficient mice, possibly through inhibiting expression of the inflammatory mediators in plaque and reduced synthesis of MMP-9 and MMP-13^[2].
Animal Research	Animal Models	Murine model of kidney I/R (background: C57BL/6)
	Dosages	5-10 mg/kg
	Administration	i.p.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT00436787	Completed	Venous Thrombosis\|Pulmonary Embolism	University of Pittsburgh\|GlaxoSmithKline	February 2007	Phase 2

References

Chemical Information & Solubility

Molecular Weight	1728.08	Formula	C₃₁H₄₃N₃O₄₉S₈.10Na
CAS No.	114870-03-0	SDF	Download Fondaparinux Sodium (Org 31540) SDF
Smiles	COC1C(C(C(C(O1)COS(=O)(=O)[O-])OC2C(C(C(C(O2)C(=O)[O-])OC3C(C(C(C(O3)COS(=O)(=O)[O-])OC4C(C(C(C(O4)C(=O)[O-])OC5C(C(C(C(O5)COS(=O)(=O)[O-])O)O)NS(=O)(=O)[O-])O)O)OS(=O)(=O)[O-])NS(=O)(=O)[O-])O)OS(=O)(=O)[O-])O)NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

Water : 100 mg/mL

DMSO : Insoluble ( Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):